Yan Ming 4

What Happened
Yan Ming, Chief Technology Officer and director of Cytek Biosciences (CTKB), had 1,332 restricted stock units (RSUs) convert into common shares on February 18, 2026. The conversion/settlement carried an effective exercise price of $0.00 (i.e., RSU vesting rather than a paid option exercise). To satisfy tax withholding obligations, 395 of the shares were surrendered to the company at $4.20 per share (total $1,659), leaving a net issuance of 937 shares to Yan Ming. This was a vesting/settlement event, not an open-market purchase or sale.

Key Details

• Transaction date: February 18, 2026; Form 4 filed February 20, 2026 (timely filing).
• Gross shares converted/vested: 1,332 RSUs → 1,332 shares (derivative conversion, code M).
• Tax withholding: 395 shares withheld/surrendered to issuer at $4.20/share = $1,659 (code F).
• Net shares delivered to insider: 937 shares (1,332 − 395).
• Exercise/Conversion price: $0.00 (RSU conversion, no cash paid).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 clarifies an RSU equals one contingent share; F2 confirms shares were withheld to satisfy tax withholding; F3 shows these RSUs vest quarterly over four years (4/48 on May 18, 2022, then 3/48 each subsequent quarter).

Context
This is a routine equity compensation vesting event and a cashless/net settlement for taxes. Such withholding is standard practice and does not represent an open-market sale or an independent purchase decision by the insider.